Minirin

Polyuria, Nocturia, Polydipsia + 14 more
Treatment
17 Active Studies for Minirin

What is Minirin

DesmopressinThe Generic name of this drug
Treatment SummaryDesmopressin is a synthetic hormone used to control the amount of water in the body. It is typically used to treat conditions such as nocturnal enuresis (bed-wetting) and diabetes insipidus. It can also be used to treat mild cases of hemophilia and von Willebrand's disease. Desmopressin is available in various forms, including intranasal solution, intravenous solution, oral tablet, and oral lyophilisate. Nocdurna, a form of desmopressin acetate, was approved by the FDA in 2018 to treat nocturia
Ddavpis the brand name
image of different drug pills on a surface
Minirin Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Ddavp
Desmopressin
1978
101

Effectiveness

How Minirin Affects PatientsDesmopressin is a drug that imitates the natural antidiuretic hormone (ADH) in the body. It works by stimulating receptors in the kidneys to absorb more water and produce less urine. Desmopressin is especially effective in increasing the activity of a protein called factor VIII, which is deficient in people with hemophilia and von Willebrand's disease Type I. Desmopressin does not have the same effect on blood pressure as ADH does. When taken as a nasal spray, desmopressin is less effective than when taken as an injection.
How Minirin works in the bodyWhen desmopressin binds to special receptors in the cells of the distal tubules and collecting ducts of the nephron, it triggers a series of reactions in the cell. This causes more water channels (aquaporins) to be inserted into the membrane of the cell, which makes it more permeable to water.

When to interrupt dosage

The dosage of Minirin is contingent upon the diagnosed ailment, including Minor Surgical Procedures, Pituitary Gland and Surgery, Hemophilia A. The amount is dependent on the technique of delivery as stated in the table hereunder.
Condition
Dosage
Administration
Nocturia
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Polydipsia
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
von Willebrand Disease
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Hemophilia A
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Pituitary Diseases
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Uremia
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Hemorrhage
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
von Willebrand Disease
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Hemorrhage
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Hemophilia A
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Diabetes Insipidus, Neurogenic
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Pituitary Surgery
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Polyuria
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Nocturnal Enuresis
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Minor Surgical Procedures
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Polyuria
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous
Hemophilia A
0.1 mg, 0.2 mg, , 0.1 mg/mL, 0.004 mg/mL, 0.0001 mg/mL, 0.01 mg, 0.06 mg, 0.12 mg, 0.24 mg, 0.025 mg, 0.05 mg, 1.5 mg/mL, 0.00083 mg, 0.00166 mg, 0.0277 mg, 0.0553 mg, 0.015 mg/mL, 0.01 mg/pump actuation, 0.15 mg/pump actuation
, Oral, Tablet, Tablet - Oral, Nasal, Solution, Solution - Nasal, Intravenous, Solution - Intravenous, Intravenous; Subcutaneous, Injection, solution, Injection, solution - Intravenous; Subcutaneous, Injection, Injection - Intravenous, Spray, Spray - Nasal, Intramuscular; Intravenous; Subcutaneous, Liquid, Liquid - Intramuscular; Intravenous; Subcutaneous, Spray, metered, Spray, metered - Nasal, Sublingual, Tablet, orally disintegrating - Sublingual, Tablet, orally disintegrating, Aerosol, metered, Aerosol, metered - Nasal, Tablet - Sublingual, Injection - Intravenous; Subcutaneous, Solution - Intramuscular; Intravenous; Subcutaneous, Solution - Intravenous; Subcutaneous

Warnings

Minirin has three contraindications. It should not be taken when experiencing any of the conditions presented in the following table.Minirin Contraindications
Condition
Risk Level
Notes
Hyponatremia
Do Not Combine
Renal Insufficiency
Do Not Combine
Hyponatremia
Do Not Combine
There are 20 known major drug interactions with Minirin.
Common Minirin Drug Interactions
Drug Name
Risk Level
Description
1-benzylimidazole
Minor
The risk or severity of hypertension can be increased when Desmopressin is combined with 1-benzylimidazole.
2,5-Dimethoxy-4-ethylamphetamine
Minor
The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine
Minor
The risk or severity of hypertension can be increased when Desmopressin is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
Minor
The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
Minor
The risk or severity of hypertension can be increased when Desmopressin is combined with 4-Methoxyamphetamine.
Minirin Toxicity & Overdose RiskTaking too much desmopressin can lead to low sodium levels in the blood (hyponatremia). Symptoms of hyponatremia can include seizures, confusion, drowsiness, headaches, irregular heartbeat, and swelling. If you have taken too much desmopressin, you should reduce the dose or stop using it altogether. You should also get your sodium levels checked and seek medical treatment.

Minirin Novel Uses: Which Conditions Have a Clinical Trial Featuring Minirin?

30 active investigations are examining the potential of Minirin to ameliorate Polyuria, Hemophilia A and Hemophilia B.
Condition
Clinical Trials
Trial Phases
Pituitary Diseases
0 Actively Recruiting
Hemorrhage
0 Actively Recruiting
Pituitary Surgery
0 Actively Recruiting
von Willebrand Disease
5 Actively Recruiting
Phase 3, Phase 1, Phase 2
Hemophilia A
3 Actively Recruiting
Phase 3, Phase 1
Uremia
0 Actively Recruiting
Nocturia
3 Actively Recruiting
Phase 4, Not Applicable
Polyuria
0 Actively Recruiting
Minor Surgical Procedures
0 Actively Recruiting
von Willebrand Disease
0 Actively Recruiting
Polydipsia
0 Actively Recruiting
Diabetes Insipidus, Neurogenic
2 Actively Recruiting
Phase 1, Early Phase 1
Hemophilia A
0 Actively Recruiting
Polyuria
0 Actively Recruiting
Hemorrhage
0 Actively Recruiting
Hemophilia A
0 Actively Recruiting
Nocturnal Enuresis
4 Actively Recruiting
Phase 3, Not Applicable

Minirin Reviews: What are patients saying about Minirin?

3.3Patient Review
10/20/2015
Minirin for Bedwetting
This medication wasn't effective every day, but it did work some days.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about minirin

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is Minirin used for?

"Minirin tablets are indicated to treat cranial diabetes insipidus and primary nocturnal enuresis (bedwetting) in patients from 6 years of age who are refractory to an alarm system or for whom an alarm system is not appropriate."

Answered by AI

Is Minirin over the counter?

"This medicine only requires a prescription from your doctor if you have low levels of specific agents that result in less bleeding."

Answered by AI

How do you give a Minirin?

"Place the Minirin Melt under your tongue. It will dissolve without needing any water. Please read the instruction leaflet that comes with the Minirin Melt."

Answered by AI

How long can you take Minirin for?

"The recommended amount of time to take Minirin Tablets for bedwetting is 3 months. After this period, it is recommended that you take a week break from the medication to see if the bedwetting has stopped. If it has not stopped, continue taking the medication for another 3 months. Your doctor will advise you on the best course of action."

Answered by AI

Clinical Trials for Minirin

Have you considered Minirin clinical trials? We made a collection of clinical trials featuring Minirin, we think they might fit your search criteria.Go to Trials
Image of Massachusetts General Hospital in Boston, United States.

Norethindrone Acetate-Ethinyl Estradiol for Oxytocin Deficiency

18 - 65
All Sexes
Boston, MA
This is an open-label, pilot study, to characterize oxytocin response to a single dose of oral Estrogen-progestin in patients with arginine-vasopressin deficiency compared to healthy controls. The association between oxytocin levels and measures of psychopathology (i.e., anxiety and depression) and quality of life across groups will be examined. We hypothesize that: 1. Salivary and blood oxytocin response to Estrogen-progestin will be lower in arginine-vasopressin deficiency compared to healthy control. 2. Lower salivary and blood oxytocin levels will be associated with more severe symptoms of anxiety, depression, and social emotional difficulties as well as lower quality of life.
Phase < 1
Recruiting
Massachusetts General HospitalElizabeth A Lawson, MD
Image of Albany Medical College in Albany, United States.

TENS for Bedwetting

5 - 17
All Sexes
Albany, NY
Children referred to pediatric urology clinic for primary nocturnal enuresis will be screened for enrollment. Patients who fail will next be offered therapy with a bedwetting alarm device or a TENS unit as an alternative, and those who chose TENS therapy will be included in the study.The patients will be randomized into two groups of 35 patients each.Group 1 will be the high pulse width set at 260us. Group 2 will be the low pulse width set at 50us. The patients will be provided with a TENS unit and electrode pads and caretakers instructed on how to use the apparatus. The child's TENS unit will be set at a pulse width determined by randomization, frequency of 10Hz, and an intensity to be determined in the office based upon when the child feels sensitive to the TENS unit. The child will be randomized and will place the electrodes along the posterior tibial nerve on the medial ankle each night before bed time for 30 minutes for a total of 30 days. Diaries including nighttime incontinence episodes and a "wet sheet" scale (dry, damp, wet, soaked) will be recorded, along with any adverse reactions to the TENS unit. Patients will be followed up after one month of TENS with evaluation including the Bowel \& Bladder Questionnaire (BBQ), a validated tool for measuring symptoms in children with voiding dysfunction \[6\]; this questionnaire will be filled out prior to starting TENS treatment in order to compare the effect of treatment. The data will be collected at different time points (baseline and after 1 month of treatment) for each group by itself and the groups compared against each other using statistical analysis.
Recruiting
Has No Placebo
Albany Medical CollegeAdam Howe, MD
Have you considered Minirin clinical trials? We made a collection of clinical trials featuring Minirin, we think they might fit your search criteria.Go to Trials
Image of Massachusetts General Hospital, Neuroendocrine Unit in Boston, United States.

Intranasal Oxytocin for Central Diabetes Insipidus

18 - 60
All Sexes
Boston, MA
This is a randomized, double-blind, placebo-controlled crossover pilot study of single-dose intranasal oxytocin (6 IU and 24 IU) vs. placebo in adult men and women (aged 18 years and above) with arginine-vasopressin deficiency to evaluate the effect of oxytocin on anxiety, depression, and socioemotional functioning (Part A), with an optional randomized, double-blind, placebo-controlled 2-week repeated dose substudy of intranasal oxytocin 6 IU or placebo (Part B). Following a screening visit to determine eligibility, participants will return for three main study visits in Part A. During the main study visits, study participants will receive either oxytocin or placebo, followed by assessments of emotional behavior. In Part A, thirty participants will be equally randomized to one of six possible groups: 1. 6 IU oxytocin - 24 IU oxytocin - placebo 2. 6 IU oxytocin - placebo - 24 IU oxytocin 3. 24 IU oxytocin - 6 IU oxytocin - placebo 4. 24 IU oxytocin - placebo - 6 IU oxytocin 5. placebo - 6 IU oxytocin - 24 IU oxytocin 6. placebo - 24 IU oxytocin - 6 IU oxytocin Following completion of the Part A crossover portion of the study, in Part B participants may also choose to continue participation in an optional, randomized, double-blind, placebo-controlled substudy of intranasal oxytocin 6 IU or placebo three times a day for two weeks, followed by assessments of emotional behavior.
Phase 1
Recruiting
Massachusetts General Hospital, Neuroendocrine UnitElizabeth A Lawson, MD, MMScTonix Pharmaceuticals, Inc.
Have you considered Minirin clinical trials? We made a collection of clinical trials featuring Minirin, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security